Coronary/Structural Heart

MyoKardia Presents Results from Phase 1a Clinical Trial of MYK-491 at the European Society of Cardiology Heart Failure Congress in Athens, Greece

First-in-Human Data for MYK-491 in Healthy Volunteers Demonstrated Well-Tolerated Increases in Cardiac Contractility Topline Results from Phase 2a Clinical Trial of MYK-491 in Patients with Stable Heart Failure with Reduced Ejection Fraction Anticipated in Second Half 2019 SOUTH SAN FRANCISCO, Calif. and ATHENS, Greece, May 28, 2019 (GLOBE NEWSWIRE) — […]

Sensible Medical Innovations Licenses ReDS™ Technology to Bayer

NETANYA, Israel, May 28, 2019 /PRNewswire/ — Sensible Medical Innovations and Bayer successfully signed an agreement making Bayer, Sensible’s largest customer in Europe. Bayer will use Sensible ReDS™ technology as an exploratory device-derived biomarker to monitor lung congestion in a clinical trial (ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03901729). The ReDS System is a wearable vest which quantifies the amount of […]

Reprieve Cardiovascular Announces Late-Breaking Acute Heart Failure Clinical Trial Data

MILFORD, Mass.–(BUSINESS WIRE)–Reprieve Cardiovascular™, a pioneering medical device company focused on improving outcomes for patients suffering from Acute Decompensated Heart Failure (ADHF), today announced the results of two non-randomized, prospective clinical trials in patients hospitalized with Acute Heart Failure (AHF). The two studies demonstrate that using Reprieve-Guided Diuretic Therapy, the […]

Acute Myocardial Infarction Patients Treated Early With Cell Therapy Delivered With BioCardia’s Helix Endocardial Delivery System Improved in Ejection Fraction and NYHA Class

PARIS and SAN CARLOS, Calif., May 23, 2019 (GLOBE NEWSWIRE) — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced positive results from a study of the company’s Helix™ Biotherapeutic Delivery System for cell therapy used to treat patients early following acute myocardial infarction (AMI) […]

Elixir Medical Announces Outstanding 9 and 12-Month Clinical and Imaging Results for the Transformational DynamX™ Bioadaptor at EuroPCR

MILPITAS, Calif. & PARIS–(BUSINESS WIRE)–Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced at EuroPCR excellent 9 and 12-month clinical and imaging data for the DynamX™ Novolimus-eluting Bioadaptor System, a next-generation coronary intervention system designed to treat blocked arteries via a novel vessel […]

Use of HeartFlow Planner Leads to Change in Treatment Strategy in Nearly Half of Patients with Coronary Heart Disease

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc., today announced new data demonstrating that the use of the investigational HeartFlow Planner, a real-time, non-invasive interactive planning tool, led to a change in treatment strategy in 45% of patients with coronary artery disease (CAD) and reduced the need for invasive physiology. The data from […]

Corindus CorPath GRX System Successfully Used in Live Complex Robotic-Assisted Coronary Intervention at EuroPCR 2019

WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today its CorPath® GRX System was successfully used to perform a live complex robotic-assisted percutaneous coronary intervention (PCI) at the EuroPCR 2019 Conference in Paris, France on Wednesday, May 22, 2019. Interventional Cardiologist, […]

Economic Analysis Shows ACIST CVi™ System Significantly Reduces Costs and Improves Patient Safety for Coronary Catheterizations Compared with Manual Injection

EDEN PRAIRIE, Minn., May 22, 2019 /PRNewswire/ — ACIST Medical Systems, a pioneering interventional and diagnostic technology company with a portfolio of advanced products for the cardiac cath lab, today announced the results of an economic analysis demonstrating the ACIST CVi contrast delivery system significantly reduces costs, increases operational efficiency and improves patient […]

Heart and Vascular Patient Care Expands to Serve Western Colorado and Eastern Utah

GRAND JUNCTION, Colo., May 22, 2019 /PRNewswire/ — SCL Health St. Mary’s Medical Center is pleased to announce the opening of a new $48.5 million, 46,000 square foot Heart & Vascular Institute in Grand Junction, Colorado. The institute brings advanced care and minimally invasive procedures to western Colorado and eastern Utah, such as TAVR/TAVI heart valve implants, other interventional […]

Neovasc Announces Positive Two-Year Follow-up Safety and Efficacy Data for the Neovasc Reducer™ in a Peer Reviewed Article in the International Journal of Cardiology

VANCOUVER, May 22, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the International Journal of Cardiology has published a […]